Appendix 4E

1. Company details

Name of entity:

Clearvue Technologies Limited

ABN:

45 071 397 487

Reporting period: Previous period:

For the year ended 30 June 2019 For the year ended 30 June 2018

2. Results for announcement to the market

			\$
Revenues from ordinary activities	up	100% to	23,029
Loss from ordinary activities after tax attributable to the owners of Clearvue Technologies Limited	up	116% to	4,265,316
Loss for the year attributable to the owners of Clearvue Technologies Limited	up	116% to	4,265,316

Dividends

No dividend has been declared or paid for the year ended 30 June 2019 (30 June 2018: \$nil).

Brief Explanation of Results

During the year ended 30 June 2019, Clearvue Technologies had been focussed on the commercialisation of the Company's technology. The Company entered into a several different Memorandums to further the development and distribution of the Clearvue products in Australia, Europe, Middle East and South Africa. The Company also received its first revenues during the financial year.

There were no other significant changes in the nature of the activities of the Company during the financial year.

The loss for the consolidated entity after providing for income tax amounted to \$4,265,316 (30 June 2018 restated: \$3,685,830).

3. Net tangible assets

	Reporting period Cents	Previous period Cents
Net tangible assets per ordinary security	1.17	3.90

4. Details of associates and joint venture entities

There are no associates or joint venture entities.

5. Details of entities over which control has been gained or lost during the period

There are no entities over which control has been gained or lost during the period.

CLEARVUE TECHNOLOGIES LIMITED AND ITS CONTROLLED ENTITIES ABN 45 071 397 487 Appendix 4E

6. Audit qualification or review

Details of audit/review dispute or qualification (if any):

The financial statements are in the process of being audited.

7. Attachments

Details of attachments (if any):

The Preliminary Financial Report of Clearvue Technologies Limited for the year ended 30 June 2019 is attached.

Date: 30 August 2019

8. Signed

Victor Rosenberg

Chairman

Perth





CLEARVUE TECHNOLOGIES LIMITED AND ITS CONTROLLED ENTITIES

ABN 45 071 397 487

Appendix 4E Preliminary Financial Report

For the year ended 30 June 2019

CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME FOR THE YEAR ENDED 30 JUNE 2019

	<u>Note</u>	Consolidated 30 Jun 2019 \$	Restated Consolidated 30 Jun 2018 \$
Revenue from contracts with customers		23,029	-
Other income	7	1,171,734	751,373
		1,194,763	751,373
Expenses			
Consulting expense		(607,631)	(298,075)
Deprecation and amortisation expense		(95,986)	(62,326)
Employee benefits expense		(835,127)	(318,271)
Finance costs		(10,271)	(29,814)
Legal fees		(38,030)	(16,375)
Material costs		(596,226)	(6,009)
Project costs		(650,614)	(756,689)
Share-based payments expense		(1,478,492)	(2,305,635)
Travel expenses		(600,907)	(131,450)
Other expenses		(546,795)	(512,559)
		(5,460,079)	(4,437,203)
Loss before income tax		(4,265,316)	(3,685,830)
Income tax expense		-	-
Loss for the year		(4,265,316)	(3,685,830)
Other comprehensive income / (loss)		-	-
Total comprehensive loss for the year		(4,265,316)	(3,685,830)
Loss per share attributable to the owners of the Company (cents)			
Basic earnings per share	9	(4.40)	(7.87)
Diluted earnings per share	9	(4.40)	(7.87)

CONSOLIDATED STATEMENT OF FINANCIAL POSITION AS AT 30 JUNE 2019

	<u>Note</u>	Consolidated 30 Jun 2019 \$	Restated Consolidated 30 Jun 2018 \$
<u>ASSETS</u>			
Current Assets			
Cash and cash equivalents		1,376,936	3,818,763
Trade and other receivables		211,073	18,797
Other assets		90,208	99,791
		1,678,217	3,937,351
Non-Current Assets			
Plant and equipment		128,022	108,376
Intangible assets	3	1,877,072	1,493,159
Other assets		55,354	-
		2,060,448	1,601,535
Total Assets		3,738,665	5,538,886
LIABILITIES Current Liabilities	4	005.055	240.050
Trade and other payables Provisions	4	625,855	316,952
Provisions		81,148 707,003	216.052
		707,003	316,952
Non-Current Liabilities			
Provisions		6,552	-
		6,552	
Total Liabilities		713,555	316,952
Net Assets		3,025,110	5,221,934
FOURTY			
EQUITY Share capital	5	10,681,302	9,993,302
Share-based payments reserve	6	4,223,027	2,842,535
Accumulated losses	O	(11,879,219)	(7,613,903)
, local indication location		(11,010,210)	(1,010,000)
Total Equity		3,025,110	5,221,934

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY FOR THE YEAR ENDED 30 JUNE 2019

	Share Capital	Share Application Monies	Share- Based Payments Reserve	Accumulated Losses	Total
	\$	\$	\$	\$	\$
Balance at 1 July 2017	4,880,646	98,000	536,900	(3,928,073)	1,587,473
Loss for the year	-	-	-	(3,441,590)	(3,441,59 0)
Other comprehensive income	-	-	-	-	-
Total comprehensive loss for the year	-	-	-	(3,441,590)	(3,441,59
Issue of ordinary shares	6,530,955	(98,000)	-	-	6,432,955
Share issue costs	(1,418,299)	_	_	_	(1,418,29
logue of listed entions	(.,,=00)		225,635		9)
Issue of listed options Share-based payments	-	_	2,080,000	-	225,635 2,080,000
Charo bacca paymonic			2,000,000		2,000,000
Balance at 30 June 2018	9,993,302	-	2,842,535	(7,369,663)	5,466,174
Prior period adjustment (Note 3)	-	-	-	(244,240)	(244,240)
Balance at 30 June 2018 – (Restated)	9,993,302	-	2,842,535	(7,613,903)	5,221,934
Balance at 1 July 2018	9,993,302	-	2,842,535	(7,613,903)	5,221,934
Loss for the year	-	-	-	(4,265,316)	(4,265,31 6)
Other comprehensive	_	_	_	_	_
income					(4.005.04
Total comprehensive loss for the year	-	-	-	(4,265,316)	(4,265,31 6)
Options exercised	590,000	-	-	-	590,000
Shares issued	98,000	-	-	-	98,000
Share-based payments	-	-	1,380,492	-	1,380,492
Balance at 30 June 2019	10,681,302	-	4,223,027	(11,879,219)	3,025,110

CONSOLIDATED STATEMENT OF CASH FLOWS FOR THE YEAR ENDED 30 JUNE 2019

Cash flows from operating activities (4,265,316) (3,685,830) Loss before income tax (4,265,316) (3,685,830) Adjustment for: 2 14,035 Depreciation of plant and equipment 34,592 14,035 Amortisation of intangible assets 61,394 48,291 Research and development net rebate (511,358) - Share-based payments 1,478,492 2,305,635 Operating loss before working capital: (1,317,869) (1,317,869) Changes in working capital: (1,017,869) (1,317,869) Changes in working capital: (1,018,30) (1,317,869) Changes in working capital: (1,018,30) (1,317,869) Changes in working capital: (1,018,30) (1,317,869) Increase in trade and other receivables (2,276) (91,983) Increase in trade and other payables 10,8,994 59,365 Increase in trade and other payables 10,8,994 59,365 Increase in trade and other payables (2,998,195) (1,350,487) Cash flows from investing activities (2,998,195) (1,350,4			<u>Note</u>	Consolidated 30 Jun 2019 \$	Restated Consolidated 30 Jun 2018 \$
Loss before income tax (4,265,316) (3,685,830) Adjustment for:	Cash flows from ope	rating activities			
Depreciation of plant and equipment 34,592 14,035 Amortisation of intangible assets 61,394 48,291 Research and development net rebate (511,358) - Share-based payments 1,478,492 2,305,635 Operating loss before working capital (3,202,196) (1,317,869) Changes in working capital: (Increase) in trade and other receivables (2,276) (91,983) Decrease in other assets 9,583 - Increase in trade and other payables 108,994 59,365 Increase in provisions 87,700 - Net cash (used in) operating activities (2,998,195) (1,350,487) Cash flows from investing activities (2,998,195) (1,350,487) Cash flows from investing activities (280,207) (233,539) Research and development expenditure (615,803) (729,983) Research and development grant received 478,777 504,918 Proceeds for deposits (55,354) - Purchase of plant and equipment (54,238) (121,655) Net cash (used in) investing activities <	Loss before income ta	_		(4,265,316)	(3,685,830)
Amortisation of intangible assets 61,394 48,291 Research and development net rebate (511,358) - Share-based payments 1,478,492 2,305,635 Operating loss before working capital (3,202,196) (1,317,869) Changes in working capital: (Increase) in trade and other receivables (2,276) (91,983) Decrease in other assets 9,583 - Increase in trade and other payables 108,994 59,365 Increase in provisions 87,700 - Net cash (used in) operating activities (2,998,195) (1,350,487) Cash flows from investing activities (280,207) (233,539) Research and trademarks expenditure (815,803) (729,983) Research and development expenditure (615,803) (729,983) Research and development grant received 478,777 504,918 Proceeds for deposits (55,354) - Purchase of plant and equipment (54,2238) (121,655) Net cash (used in) investing activities (33,632) (355,195) Cash flows from financing activities	•	nd equipment		34,592	14,035
Share-based payments 1,478,492 2,305,635 Operating loss before working capital (3,202,196) (1,317,869) Changes in working capital: (Increase) in trade and other receivables (2,276) (91,983) Decrease in other assets 9,583 - Increase in trade and other payables 108,994 59,365 Increase in provisions 87,700 - Net cash (used in) operating activities (2,998,195) (1,350,487) Cash flows from investing activities (2,998,195) (1,350,487) Patents and trademarks expenditure (280,207) (233,539) Research and development expenditure (615,803) (729,983) Research and development rebate 493,195 225,064 Research and development grant received 478,777 504,918 Proceeds for deposits (55,354) - Purchase of plant and equipment (54,238) (121,655) Net cash (used in) investing activities (33,632) (355,195) Cash flows from financing activities 590,000 - Share issuance cost -				61,394	48,291
Operating loss before working capital (3,202,196) (1,317,869) Changes in working capital: (Increase) in trade and other receivables (2,276) (91,983) Decrease in trade and other assets 9,583 - Increase in trade and other payables 108,994 59,365 Increase in provisions 87,700 - Net cash (used in) operating activities (2,998,195) (1,350,487) Cash flows from investing activities (280,207) (233,539) Patents and trademarks expenditure (815,803) (729,983) Research and development expenditure (615,803) (729,983) Research and development grant received 478,777 504,918 Proceeds for deposits (55,354) - Purchase of plant and equipment (54,238) (121,655) Net cash (used in) investing activities (33,632) (355,195) Cash flows from financing activities 590,000 - Options exercised 590,000 5,528,000 Share issuance cost - (513,344) Net cash from financing activities 590,000 <td>Research and develop</td> <td>ment net rebate</td> <td></td> <td>(511,358)</td> <td>-</td>	Research and develop	ment net rebate		(511,358)	-
Changes in working capital: (Increase) in trade and other receivables (2,276) (91,983) Decrease in other assets 9,583 - Increase in trade and other payables 108,994 59,365 Increase in provisions 87,700 - Net cash (used in) operating activities (2,998,195) (1,350,487) Cash flows from investing activities (280,207) (233,539) Patents and trademarks expenditure (615,803) (729,983) Research and development expenditure (615,803) (729,983) Research and development rebate 493,195 225,064 Research and development grant received 478,777 504,918 Proceeds for deposits (55,354) - Purchase of plant and equipment (54,238) (121,655) Net cash (used in) investing activities (33,632) (355,195) Cash flows from financing activities 590,000 - Share issuance cost - (513,344) Net cash from financing activities 590,000 5,014,656 Net increase in bank balances (2,441,827)	Share-based payment	S		1,478,492	2,305,635
(Increase) in trade and other receivables (2,276) (91,983) Decrease in other assets 9,583 - Increase in trade and other payables 108,994 59,365 Increase in provisions 87,700 - Net cash (used in) operating activities (2,998,195) (1,350,487) Cash flows from investing activities (280,207) (233,539) Patents and trademarks expenditure (615,803) (729,983) Research and development expenditure (615,803) (729,983) Research and development grant received 478,777 504,918 Proceeds for deposits (55,354) - Purchase of plant and equipment (54,238) (121,655) Net cash (used in) investing activities (33,632) (355,195) Cash flows from financing activities 590,000 - Options exercised 590,000 - Issuance of ordinary shares - 5,528,000 Share issuance cost - (513,344) Net cash from financing activities 590,000 5,014,656 Net increase in bank bala	Operating loss befor	e working capital		(3,202,196)	(1,317,869)
Decrease in other assets 9,583 1	Changes in working ca	apital:			
Increase in trade and other payables 108,994 59,365 Increase in provisions 87,700 - Net cash (used in) operating activities (2,998,195) (1,350,487) Cash flows from investing activities (280,207) (233,539) Patents and trademarks expenditure (615,803) (729,983) Research and development expenditure (615,803) (729,983) Research and development grant received 478,777 504,918 Proceeds for deposits (55,354) - Purchase of plant and equipment (54,238) (121,655) Net cash (used in) investing activities (33,632) (355,195) Cash flows from financing activities 590,000 - Options exercised 590,000 - Issuance of ordinary shares - (513,344) Net cash from financing activities 590,000 5,014,656 Net increase in bank balances (2,441,827) 3,308,974 Bank balances at beginning of year 3,818,763 509,789	•			(2,276)	(91,983)
Increase in provisions				· · · · · · · · · · · · · · · · · · ·	-
Net cash (used in) operating activities (2,998,195) (1,350,487) Cash flows from investing activities (280,207) (233,539) Patents and trademarks expenditure (615,803) (729,983) Research and development expenditure (615,803) (729,983) Research and development rebate 493,195 225,064 Research and development grant received 478,777 504,918 Proceeds for deposits (55,354) - Purchase of plant and equipment (54,238) (121,655) Net cash (used in) investing activities (33,632) (355,195) Cash flows from financing activities 590,000 - Options exercised 590,000 - Issuance of ordinary shares - (513,344) Net cash from financing activities 590,000 5,014,656 Net increase in bank balances (2,441,827) 3,308,974 Bank balances at beginning of year 3,818,763 509,789		other payables		· · · · · · · · · · · · · · · · · · ·	59,365
Cash flows from investing activities (280,207) (233,539) Patents and trademarks expenditure (615,803) (729,983) Research and development expenditure (615,803) (729,983) Research and development rebate 493,195 225,064 Research and development grant received 478,777 504,918 Proceeds for deposits (55,354) - Purchase of plant and equipment (54,238) (121,655) Net cash (used in) investing activities (33,632) (355,195) Cash flows from financing activities 590,000 - Options exercised 590,000 - Issuance of ordinary shares - (513,344) Net cash from financing activities 590,000 5,014,656 Net increase in bank balances (2,441,827) 3,308,974 Bank balances at beginning of year 3,818,763 509,789	· · · · · · · · · · · · · · · · · · ·				
Patents and trademarks expenditure (280,207) (233,539) Research and development expenditure (615,803) (729,983) Research and development rebate 493,195 225,064 Research and development grant received 478,777 504,918 Proceeds for deposits (55,354) - Purchase of plant and equipment (54,238) (121,655) Net cash (used in) investing activities (33,632) (355,195) Cash flows from financing activities 590,000 - Options exercised 590,000 - Issuance of ordinary shares - 5,528,000 Share issuance cost - (513,344) Net cash from financing activities 590,000 5,014,656 Net increase in bank balances (2,441,827) 3,308,974 Bank balances at beginning of year 3,818,763 509,789	Net cash (used in) op	erating activities		(2,998,195)	(1,350,487)
Research and development expenditure (615,803) (729,983) Research and development rebate 493,195 225,064 Research and development grant received 478,777 504,918 Proceeds for deposits (55,354) - Purchase of plant and equipment (54,238) (121,655) Net cash (used in) investing activities (33,632) (355,195) Cash flows from financing activities 590,000 - Options exercised 590,000 - Issuance of ordinary shares - 5,528,000 Share issuance cost - (513,344) Net cash from financing activities 590,000 5,014,656 Net increase in bank balances (2,441,827) 3,308,974 Bank balances at beginning of year 3,818,763 509,789		_			
Research and development rebate 493,195 225,064 Research and development grant received 478,777 504,918 Proceeds for deposits (55,354) - Purchase of plant and equipment (54,238) (121,655) Net cash (used in) investing activities (33,632) (355,195) Cash flows from financing activities 590,000 - Options exercised 590,000 - Issuance of ordinary shares - (513,344) Net cash from financing activities 590,000 5,014,656 Net increase in bank balances (2,441,827) 3,308,974 Bank balances at beginning of year 3,818,763 509,789		·			, ,
Research and development grant received 478,777 504,918 Proceeds for deposits (55,354) - Purchase of plant and equipment (54,238) (121,655) Net cash (used in) investing activities (33,632) (355,195) Cash flows from financing activities 590,000 - Options exercised 590,000 - Issuance of ordinary shares - (513,344) Net cash from financing activities 590,000 5,014,656 Net increase in bank balances (2,441,827) 3,308,974 Bank balances at beginning of year 3,818,763 509,789	•	•		, ,	
Proceeds for deposits (55,354) - Purchase of plant and equipment (54,238) (121,655) Net cash (used in) investing activities (33,632) (355,195) Cash flows from financing activities 590,000 - Options exercised 590,000 - Issuance of ordinary shares - (513,344) Net cash from financing activities 590,000 5,014,656 Net increase in bank balances (2,441,827) 3,308,974 Bank balances at beginning of year 3,818,763 509,789				· ·	
Purchase of plant and equipment (54,238) (121,655) Net cash (used in) investing activities (33,632) (355,195) Cash flows from financing activities 590,000 - Options exercised 590,000 - Issuance of ordinary shares - (513,344) Net cash from financing activities 590,000 5,014,656 Net increase in bank balances (2,441,827) 3,308,974 Bank balances at beginning of year 3,818,763 509,789	•	ment grant received		· ·	504,918
Net cash (used in) investing activities (33,632) (355,195) Cash flows from financing activities 590,000 - Options exercised 590,000 - Issuance of ordinary shares - 5,528,000 Share issuance cost - (513,344) Net cash from financing activities 590,000 5,014,656 Net increase in bank balances (2,441,827) 3,308,974 Bank balances at beginning of year 3,818,763 509,789	·			•	(404.055)
Cash flows from financing activitiesOptions exercised590,000-Issuance of ordinary shares-5,528,000Share issuance cost-(513,344)Net cash from financing activities590,0005,014,656Net increase in bank balances(2,441,827)3,308,974Bank balances at beginning of year3,818,763509,789	•				
Options exercised 590,000 - Issuance of ordinary shares - 5,528,000 Share issuance cost - (513,344) Net cash from financing activities 590,000 5,014,656 Net increase in bank balances (2,441,827) 3,308,974 Bank balances at beginning of year 3,818,763 509,789	Net cash (used in) in	vesting activities		(33,632)	(355,195)
Issuance of ordinary shares - 5,528,000 Share issuance cost - (513,344) Net cash from financing activities 590,000 5,014,656 Net increase in bank balances (2,441,827) 3,308,974 Bank balances at beginning of year 3,818,763 509,789		ncing activities		500.000	
Share issuance cost - (513,344) Net cash from financing activities 590,000 5,014,656 Net increase in bank balances (2,441,827) 3,308,974 Bank balances at beginning of year 3,818,763 509,789	·			590,000	-
Net cash from financing activities 590,000 5,014,656 Net increase in bank balances (2,441,827) 3,308,974 Bank balances at beginning of year 3,818,763 509,789	•	nares		-	· ·
Net increase in bank balances (2,441,827) 3,308,974 Bank balances at beginning of year 3,818,763 509,789		!		-	
Bank balances at beginning of year 3,818,763 509,789	Net cash from financ	ing activities		590,000	5,014,656
	Net increase in bank b	alances		(2,441,827)	3,308,974
Bank balances at end of year 1,376,936 3,818,763	Bank balances at begi	nning of year		3,818,763	509,789
	Bank balances at end	d of year		1,376,936	3,818,763

NOTES TO PRELIMINARY FINANCIAL REPORT FOR THE YEAR ENDED 30 JUNE 2019

These notes form an integral part of and should be read in conjunction with the accompanying financial report:

1. BASIS OF PREPARATION

This preliminary financial report has been prepared in accordance with Australian Securities Exchange Listing Rules as they relate to the Appendix 4E and in accordance with the recognition and measurement requirements of the Australian Accounting Standards, other authoritative pronouncements of the Australian Accounting Standards Board, Urgent Issues Group Interpretations and the *Corporations Act 2001*.

As such, this preliminary financial report does not include all the notes of the type included in an annual financial report and accordingly, should be read in conjunction with the annual report for the year ended 30 June 2018 and with any public announcement made by Clearvue Technologies Limited during the period in accordance with the continuous disclosure requirements of the *Corporations Act* 2001.

The principal accounting policies adopted in the preparation of the financial report are consistent with those of the previous financial year.

2. RESTATEMENT

During the year ended 30 June 2019, it was agreed to restate prior deferred development costs, project revenue and costs associated with the Greenhouse project year (as stated below). The restatement is to ensure that the relevant project revenue and costs are treated appropriately according to AASB 120 Government Grants and Disclosure of Government Assistance. Extracts (being only those line items affected) are disclosed below.

Consolidated Statement of Profit or Loss and Other Comprehensive Income (Extract)

	Reported		Restated
	30 Jun 2018	<u>Adjustment</u>	30 Jun 2018
	\$	\$	\$
Revenue	75,143	(75,143)	-
Other income	432,368	319,005	751,373
Total revenue	507,511	243,862	751,373
Project costs	(268,587)	(488,102)	(756,689)
Loss before income tax	(3,441,590)	(244,240)	(3,685,830)
Loss for the year, representing total comprehensive loss of the half-year	(3,441,590)	(244,240)	(3,685,830)
Basic loss per share Diluted loss per share	Cents (7.35) (7.35)	Cents (0.52) (0.52)	Cents (7.87) (7.87)

NOTES TO PRELIMINARY FINANCIAL REPORT FOR THE YEAR ENDED 30 JUNE 2019

2. RESTATEMENT (CONT'D)

Consolidated Statement of Financial	Position (Extract)		
	Reported		Restated
	Consolidated		Consolidated
	30 Jun 2018	<u>Adjustment</u>	30 Jun 2018
	\$	\$	\$
Trade and other receivables	-	18,797	18,797
Total current assets	3,918,554	18,797	3,937,351
Intangible assets	1,756,196	(263,037)	1,493,159
Total non-current assets	1,864,572	(263,037)	1,601,535
Total assets	5,783,126	(244,240)	5,538,886
Net assets	5,466,174	(244,240)	5,221,934
Accumulated losses	(7,369,663)	(244,240)	(7,613,903)
Total equity	5,466,174	(244,240)	5,221,934

Consolidated Statement of Cash Flows (Extract)

	Reported Consolidated 30 Jun 2018 \$	<u>Adjustment</u> \$	Restated Consolidated <u>30 Jun 2018</u> \$
Cash flows from operating activities	·	·	·
Loss before income tax	(3,441,590)	(244,240)	(3,685,830)
Operating loss before working capital	(1,073,629)	(244,240)	(1,317,869)
(Increase) / decrease in other receivables	(73,186)	(18,797)	(91,983)
Net cash used in operating activities	(1,087,450)	(263,037)	(1,350,487)
Cash flows from investing activities Research and development	(202 222)	(400.045)	(700,000)
expenditure	(263,038)	(466,945)	(729,983)
Research and development rebate	-	225,064	225,064
Research and development grant received	-	504,918	504,918
Net cash used in investing activities	(618,232)	263,037	(355,195)

NOTES TO PRELIMINARY FINANCIAL REPORT FOR THE YEAR ENDED 30 JUNE 2019

2. RESTATEMENT (CONT'D)

	Reported Consolidated 30 Jun 2018 \$	Adjustment \$	Restated Consolidated 30 Jun 2018 \$
Intangible assets		()	
Research and development	844,057	(263,037)	581,020
Total	1,756,196	(263,037)	1,493,159
Other income			
Rebates and refunds	-	225,064	225,064
Total	432,368	225,064	751,373

3. INTANGIBLE ASSETS

		Destated.
	Consolidated 30 Jun 2019 \$	Restated Consolidated 30 Jun 2018 \$
Patents and trademarks	1,182,431	912,139
Research and development	694,641	581,020
Trooparon and actorophilonic	1,877,072	1,493,159
Patents and trademarks		
Cost	1,433,641	1,101,955
Less accumulated amortisation	(251,210)	(189,816)
Carrying amount	1,182,431	912,139
Cost		
Balance at 1 July	1,101,955	868,416
Additions	331,686	233,539
Balance at 30 June	1,433,641	1,101,955
Accumulated amortisation		
Balance at 1 July	189,816	141,525
Amortisation for the year	61,394	48,291
Balance at 30 June	251,210	189,816
Balance at 30 June	1,182,431	912,139

NOTES TO PRELIMINARY FINANCIAL REPORT FOR THE YEAR ENDED 30 JUNE 2019

3. INTANGIBLE ASSETS (CONT'D)

	Consolidated 30 Jun 2019 \$	Restated Consolidated 30 Jun 2018 \$
Research and development		
Cost		
Balance at 1 July	581,020	581,020
Additions	113,621	-
Balance at 30 June	694,641	581,020
Accumulated amortisation		
Balance at 1 July	-	-
Amortisation for the year	<u> </u>	
Balance at 30 June	-	<u> </u>
Carrying amount at 30 June	694,641	581,020
Net carrying amount	1,877,072	1,493,159

Intangible assets are stated at cost. The useful life of these patents and trademarks is estimated to be finite.

4. TRADE AND OTHER PAYABLES

	Consolidated <u>30 Jun 2019</u> \$	Consolidated 30 Jun 2018 \$
Trade payables	578,333	287,203
Other payables	47,522	27,379
Accruals	-	2,370
	625,855	316,952

NOTES TO PRELIMINARY FINANCIAL REPORT FOR THE YEAR ENDED 30 JUNE 2019

5. SHARE CAPITAL

	30 Jun 2019 NO. OF SHARES	30 Jun 2018 NO. OF SHARES	<u>30 Jun 2019</u> \$	30 Jun 2018 \$
Share issued and fully paid				
Balance at 1 July	95,020,300	61,433,023	9,993,302	4,880,646
Options exercised ¹	2,360,000	-	590,000	-
Issue of shares to KMP ²	350,000	-	98,000	-
Issue of shares pre-IPO	-	4,062,501	-	626,000
Issue of shares IPO	-	25,000,000	-	5,000,000
Issue of shares to corporate advisors	-	4,524,776	-	904,955
Share issue costs	-	-	-	(1,418,299)
Balance at 30 June	97,730,300	95,020,300	10,681,302	9,993,302

¹ On the 21 September 2018, 1,860,000 unlisted options were exercised at an exercise price of \$0.25 per option. Subsequently, on the 5 October 2018, 500,000 unlisted options were exercised at an exercise price of \$0.25 per option.

The share capital of the Company consists only of fully paid ordinary shares, the shares do not have a par value. All shares are equally eligible to receive dividends and the repayment of capital and represent one vote at the shareholders' meeting of the Company. The balance includes 39,026,956 fully paid ordinary shares that are held in escrow for 24 months from the date of official quotation.

6. SHARE-BASED PAYMENTS RESERVE

	Consolidated <u>30 Jun 2019</u> \$	Consolidated <u>30 Jun 2018</u> \$
Share plan for Directors *	536,900	536,900
Options issued to Lead Manager Offer	225,635	225,635
Options issued to Consultants	1,380,492	-
Performance shares to Directors	2,080,000	2,080,000
	4,223,027	2,842,535

^{*} The share plan arises on the grant of loan for a term of 10 years to Directors and related parties for the purchase of the Company's ordinary shares under the Clearvue Loan Funded Share Plan in 2017. Amounts are transferred out of the reserve and into share capital when the loans are settled.

² On 1 February 2019, 350,000 fully paid ordinary shares were issued at nil consideration, pursuant to the Company's Employee Share Plan. The shares were valued at a fair value of \$0.28 per share.

NOTES TO PRELIMINARY FINANCIAL REPORT FOR THE YEAR ENDED 30 JUNE 2019

SHARE-BASED PAYMENTS RESERVE (CONT'D)		
	NO. OF	
Movement in Options	OPTIONS	\$
Balance at 1 July 2017	54,458,024	536,900
Options issued to Lead Managers (Note 9)	2,500,000	225,635
Balance at 1 July 2018	56,958,024	762,535
Options exercised (Note 9)	(2,360,000)	-
Options issued to Consultants (Note 9)	8,550,000	1,380,492
Balance at 30 June 2019	63,148,024	2,143,027

7. OTHER INCOME

6.

	Consolidated 30 Jun 2019 \$	Restated Consolidated 30 Jun 2018 \$
Government grant	423,735	429,776
Other grants	55,042	93,941
Rebates and refunds	683,195	225,064
Interest received	9,762	2,592
	1,171,734	751,373

8. SHARE-BASED PAYMENTS EXPENSE

Shares Issued

On 1 February 2019, 350,000 fully paid ordinary shares were issued at nil consideration to an employee pursuant to the Company's Employee Share Plan. Shares were valued at grant date at \$0.28 per share for a total value of \$98,000.

Performance Shares Issued

On 16 January 2018, 13,000,000 performance shares were issued to two of the Directors on achievement of certain milestones. Mr V Rosenberg was issued 1,000,000 Class A Performance Shares, 3,000,000 Class B Performance Shares and 6,000,000 Class C Performance Shares. Mr Lyford was issued 1,000,000 Class D Performance Shares, 1,000,000 Class E Performance Shares and 1,000,000 Class F Performance Shares. Performance shares are subject to escrow for 24 months from the date of official quotation.

Each Class A Performance Share, Class B Performance Share, Class C Performance Share, Class D Performance Share, Class E Performance Share and Class F Performance Share (together and each being a Performance Share) is a share in the capital of the Company.

NOTES TO PRELIMINARY FINANCIAL REPORT FOR THE YEAR ENDED 30 JUNE 2019

8. SHARE-BASED PAYMENTS EXPENSE (CONT'D)

The conversion of shares are dependent on the following: Class A Performance Shares

- (A) In the event that the aggregate of the value of the ClearVue Orders and the ClearVue Payments is equal to or greater than \$2,000,000 within a period of 24 months commencing on the date the Company is admitted to the Official List (Listing Date) (Class A Milestone 1), each Class A Performance Share will convert into one Share; or
- (B) In the event that Class A Milestone 1 is not satisfied but the aggregate of the value of the ClearVue Orders and the ClearVue Payments is equal to or greater than \$7,000,000 within a period of 36 months from the Listing Date (Class A Milestone 2), each Class A Performance Share will convert into one Share; or
- (C) In the event that neither Class A Milestone 1 or Class A Milestone 2 is satisfied but the aggregate of the value of the ClearVue Orders and the ClearVue Payments is equal to or greater than \$17,000,000 within a period of 48 months from the Listing Date, each Class A Performance Share will convert into one Share.

Class B Performance Shares

- (A) In the event that the aggregate of the value of the ClearVue Orders and the ClearVue Payments is equal to or greater than \$5,000,000 within a period of 24-36 months from the Listing Date (Class B Milestone 1), each Class B Performance Share will convert into one Share: or
- (B) In the event that Class B Milestone 1 is not satisfied but the aggregate of the value of the ClearVue Orders and the ClearVue Payments is equal to or greater than \$7,000,000 within a period of 36 months from the Listing Date (Class B Milestone 2), each Class B Performance Share will convert into one Share; or
- (C) In the event that neither Class B Milestone 1 or Class B Milestone 2 is satisfied but the aggregate of the value of the ClearVue Orders and the ClearVue Payments is equal to or greater than \$17,000,000 within a period of 48 months from the Listing Date, each Class B Performance Share will convert into one Share.

Class C Performance Shares

- (A) In the event that the aggregate of the value of the ClearVue Orders and the ClearVue Payments is equal to or greater than \$10,000,000 within a period of 36-48 months from the Listing Date (Class C Milestone 1), each Class C Performance Share will convert into one Share; or
- (B) In the event that Class C Milestone 1 is not satisfied but the aggregate of the value of the ClearVue Orders and the ClearVue Payments is equal to or greater than \$17,000,000 within a period of 48 months from the Listing Date, each Class C Performance Share will convert into one Share.

Class D Performance Shares

- (A) In the event the Company executes two Agreements within a period of 12 months from the Listing Date (Class D Milestone 1), each Class D Performance Share will convert into one Share; or
- (B) In the event that the Class D Milestone 1 is not satisfied but the Company executes four Agreements within a period of 24 months from the Listing Date, each Class D Performance Share will convert into one Share (Class D Milestone 2); or

NOTES TO PRELIMINARY FINANCIAL REPORT FOR THE YEAR ENDED 30 JUNE 2019

8. SHARE-BASED PAYMENTS EXPENSE (CONT'D)

(C) In the event that neither Class D Milestone 1 or Class D Milestone 2 is satisfied but the Company executes six Agreements within a period of 36 months from the Listing Date, each Class D Performance Share will convert into one Share.

Class E Performance Shares

- (A) In the event the Company executes two Agreements within a period of 12-24 months from the Listing Date (Class E Milestone 1), each Class E Performance Share will convert into one Share: or
- (B) In the event that Class E Milestone 1 is not satisfied but the Company executes four Agreements within a period of 24 months from the Listing Date, each Class E Performance Share will convert into one Share (Class E Milestone 2); or
- (C) In the event that neither Class E Milestone 1 or Class E Milestone 2 are satisfied but the Company executes six Agreements within a period of 36 months from the Listing Date, each Class E Performance Share will convert into one Share.

Class F Performance Shares

- (A) In the event the Company executes two Agreements within a period of 24-36 months from the Listing Date (Class F Milestone 1), each Class F Performance Share will convert into one Share; or
- (B) In the event that Class F Milestone 1 is not satisfied but the Company executes six Agreements within a period of 36 months from the Listing Date, each Class F Performance Share will convert into one Share.

At 30 June 2019 and at the date of lodgement of this report the conversion milestones for the Performance Shares have not been met and therefore no Performance Shares have been converted into fully paid ordinary shares.

Grant Date	Performance Shares	Issue Price	\$
16 January 2018	13,000,000	0.16	2,080,000

Options Issued

On 16 May 2018, 2,500,000 options to the value of \$225,635 were were issued to Ventnor Capital Pty Ltd as the Lead Manager on completion of the IPO. Each option entitles the holder to subscribe for one fully paid ordinary share in the capital of the Company upon exercise of the option.

On the 21 December 2018, 8,550,000 unlisted options exercisable at \$0.25 per option, with a total fair value of \$1,380,492, were issued to consultants of the Company for services provided. All the options vested on grant date.

The Company has measured the fair value of the options granted during the current financial year by adapting a Black-Scholes option pricing model using the following inputs:

Grant Date	Expiry Date	Exercise Price	Share Price	Volatility	Risk Free Rate
21 Dec 2018	21 Jun 2021	\$0.25	\$0.28	96.65%	1.97%

NOTES TO PRELIMINARY FINANCIAL REPORT FOR THE YEAR ENDED 30 JUNE 2019

8. SHARE-BASED PAYMENTS EXPENSE (CONT'D)

2019

Grant Date	Expiry Date	Exercise Price	Balance at the start of the year	Granted	Exercised	Expired / Forfeited / Other	Balance at the end of the year
21/06/2017	21/06/2021	\$0.25	54,458,024	-	(2,360,000)	-	52,098,024
16/05/2018	21/06/2021	\$0.25	2,500,000	-	-	-	2,500,000
21/12/2018	21/06/2021	\$0.25	-	8,550,000	-	-	8,550,000
			56,958,024	8,550,000	(2,360,000)	-	63,148,024

2018

	Expiry	Exercise	Balance at the start of			Expired / Forfeited	Balance at the end of
Grant Date	Date	Price	the year	Granted	Exercised	/ Other	the year
21/06/2017	21/06/2021	\$0.25	54,458,024	-	-	-	54,458,024
16/05/2018	21/06/2021	\$0.25	-	2,500,000	-	-	2,500,000
			54,458,024	2,500,000	-	-	56,958,024

9. LOSS PER SHARE

	Consolidated 30 Jun 2019 \$	Restated Consolidated 30 Jun 2018 \$
Loss after income tax used in calculating basic and diluted earnings per share	(4,265,316)	(3,685,830)
Weighted average number or ordinary shares used in calculating basic and diluated earnings per share	No. 96,974,766	No. 46,825,717
Basic loss per share Diluted loss per share	Cents (4.40) (4.40)	Cents (7.87) (7.87)